Drugs / taurolidine
taurolidine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DEFENCATH | — | 2023-11-15 | fda.gov ↗ |
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00022360 | May → Oct 2001 | central nervous system neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00021034 | Mar → Aug 2001 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02313883 | Jul 2015 → Jul 2018 | periodontitis | Geistlich Pharma AG | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07074821 | Mar 2023 → Feb 2024 | — | Oman Ministry of Health | Completed | No outcome recorded |
| Phase 2 | NCT04093895 | Aug 2019 → Jun 2020 | periodontitis | Geistlich Pharma AG | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06822426 | May 2025 → Jan 2028 expected | — | CorMedix | Recruiting | No outcome recorded |
| Phase 3 | NCT00321165 | Jun 2006 → Mar 2008 | infectious disease with sepsis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06714864 | Jul 2025 → Jul 2028 expected | prosthesis-related infectious disease | CorMedix | Recruiting | No outcome recorded |
| Phase 4 | NCT03539718 | May → Nov 2018 | thrombotic disease | Ain Shams University | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07366372 | May 2023 → Nov 2024 | — | Tanta University | Completed | No outcome recorded |
| — | NCT02279121 | Nov 2014 → Mar 2016 | prosthesis-related infectious disease | Centre Hospitalier Régional Metz-Thionville | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06707480 | — | — | CorMedix | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02036255 Background | May 2015 → Jul 2017 | infectious disease | University Hospital Brussels | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02515201 Comparator | Sep 2014 → Mar 2015 | prosthesis-related infectious disease | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 4 | NCT02868697 Comparator | Nov 2013 → Aug 2015 | — | Hamad Medical Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02009189 Comparator | Nov 2012 → Nov 2013 | — | Stanley Dudrick's Memorial Hospital | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | taurolidine | “1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis\[tetrahydro-1,1,1',1'-tetraoxide\], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH” NCT02868697 ↗ |
| Known as | (cyclo)-taurolidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105420 ↗ |
| Known as | PerioSept(r) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02313883 ↗ |
| Known as | Taurolidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105420 ↗ |
| Known as | Taurolidine Citrate | “Taurolidine Citrate and Unfractionated Heparin Combination Versus Unfractionated Heparin Alone in Prevention of Inflammation in Hemodialysis Catheters.” NCT03539718 ↗ |
| Known as | Taurolidine component of defencath | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105420 ↗ |
| Known as | Taurolidine component of taurolock | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105420 ↗ |
| Known as | TauroLock | “At the end of each course, she rinses again the CVC and instills TauroLock ™ solution” NCT02279121 ↗ |
| Known as | W-3100M | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105420 ↗ |
| Modality | Small molecule | — CHEMBL2105420 ↗ |
| Route | Intravenous | “Patients receive taurolidine IV over 1-4 hours” NCT00022360 ↗ |